Mitophagy is the specialized form of autophagy responsible for the selective degradation of damaged or dysfunctional mitochondria. This process is essential for maintaining cellular homeostasis, particularly in neurons, which have exceptionally high energy demands and rely heavily on mitochondrial function. The term "mitophagy" was first coined in 1998 [1] and since then has emerged as a critical mechanism in understanding neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [2]. [@matsuda2010]
Neurons present unique vulnerabilities that make mitophagy particularly crucial. Unlike most cell types, neurons are post-mitotic and cannot divide to dilute damaged components. They also have extreme longevity, with some neurons surviving for the entire lifespan of an individual. These characteristics mean that neurons must rely on robust quality control mechanisms to maintain function over decades. Mitochondrial dysfunction is among the earliest and most consistent pathological features in neurodegenerative diseases, and impaired mitophagy plays a central role in this process [3]. [@kane2014]
Mitophagy is the specialized form of autophagy responsible for the selective degradation of damaged or dysfunctional mitochondria. This process is essential for maintaining cellular homeostasis, particularly in neurons, which have exceptionally high energy demands and rely heavily on mitochondrial function. The term "mitophagy" was first coined in 1998 [1] and since then has emerged as a critical mechanism in understanding neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [2]. [@matsuda2010]
Neurons present unique vulnerabilities that make mitophagy particularly crucial. Unlike most cell types, neurons are post-mitotic and cannot divide to dilute damaged components. They also have extreme longevity, with some neurons surviving for the entire lifespan of an individual. These characteristics mean that neurons must rely on robust quality control mechanisms to maintain function over decades. Mitochondrial dysfunction is among the earliest and most consistent pathological features in neurodegenerative diseases, and impaired mitophagy plays a central role in this process [3]. [@kane2014]
The importance of mitophagy in neurodegeneration is underscored by the discovery that mutations in genes encoding mitophagy proteins cause familial forms of PD. PINK1 (PTEN-induced kinase 1) and Parkin (PRKN) are among the most frequently mutated genes in early-onset PD, directly linking mitophagy dysfunction to disease pathogenesis [4]. [@sarraf2013]
Mitochondrial quality control begins with the detection of mitochondrial damage. Multiple parallel sensing mechanisms ensure robust activation of mitophagy when mitochondria are compromised [5]: [@johansson2020]
Mitochondrial membrane potential loss: The inner mitochondrial membrane maintains a critical electrochemical gradient (Δψm) essential for ATP synthesis. When this potential drops below approximately -150 mV, the translocase of outer membrane (TOM) complex fails to import PINK1, leading to its accumulation on the outer mitochondrial membrane (OMM). This serves as the primary trigger for the PINK1-Parkin pathway [6]. [@kageyama2014]
Oxidative stress: Reactive oxygen species (ROS) generated during normal mitochondrial respiration can damage mitochondrial proteins, lipids, and mitochondrial DNA (mtDNA). Oxidatively damaged proteins require replacement, and oxidized cardiolipin exposure on the OML serves as an "eat-me" signal. The accumulation of mitochondrial ROS is particularly damaging in neurons due to their high metabolic rate and relatively low antioxidant capacity [7]. [@moore2016]
Mitochondrial DNA damage: Damage to mtDNA can result in the release of mitochondrial dsRNA and dsDNA into the cytoplasm, where they activate innate immune sensors including cGAS and MDA5. This triggers inflammatory responses and provides additional motivation for mitochondrial turnover [8]. [@heo2015]
Calcium dysregulation: Excessive cytosolic calcium accumulation in mitochondria leads to opening of the mitochondrial permeability transition pore (mPTP), causing membrane potential collapse and releasing intermembrane space proteins that signal damage [9]. [@zhou2021]
The PINK1-Parkin pathway represents the best-characterized mechanism of mitophagy initiation [10]: [@nakatogawa2020]
PINK1 stabilization: Under normal conditions, PINK1 (encoded by the PARK6 gene) is imported into mitochondria through the TOM and TIM complexes and rapidly degraded by proteases in the inner membrane. When mitochondrial membrane potential collapses, import is blocked and PINK1 accumulates on the OMM, where it can phosphorylate its substrates [11]. [@ichimura2000]
Parkin recruitment and activation: PINK1 directly phosphorylates Parkin (encoded by the PARK2 gene) at Ser65 within its ubiquitin-like domain, triggering a conformational change that activates its E3 ligase activity. PINK1 also phosphorylates ubiquitin at Ser65, creating a phospho-ubiquitin chain that enhances Parkin activation in a feedforward manner [12]. [@mizushima1998a]
Ubiquitin chain formation: Activated Parkin ubiquitinates multiple OMM proteins, including: [@bockler2014]
Autophagy receptors bridge ubiquitinated mitochondria to the forming autophagosome [14]: [@liu2022]
p62/SQSTM1: The most extensively studied autophagy receptor, p62 contains a PB1 domain for oligomerization, a ZZ-type zinc finger domain, a TBK1-binding domain, an LIR motif, and a C-terminal UBA domain that binds ubiquitin chains. p62 also has the ability to sequestrate ubiquitinated cargo into aggregates, facilitating their delivery to autophagosomes [15]. [@zhang2008]
OPTN (Optineurin): This receptor is particularly important in neurons due to its calcium-sensitive binding to ubiquitin. OPTN mutations cause familial ALS, highlighting its relevance to neurodegeneration. TBK1 phosphorylates OPTN, enhancing its affinity for ubiquitin chains and LC3 [16]. [@liu2012]
NDP52 (CALCOCO2): Originally characterized as a binding partner for damaged DNA, NDP52 specifically recognizes ubiquitin chains generated by Parkin and recruits TANK-binding kinase 1 (TBK1) to initiate autophagy [17]. [@sentelle2012]
TAX1BP1: This receptor cooperates with p62 and NDP52 in mitophagy, with phosphorylation enhancing its function [18]. [@wang2011]
Once receptors are recruited, the autophagosome formation machinery is engaged [19]: [@kaur2020]
LC3 lipidation: LC3 (microtubule-associated protein 1A/1B-light chain 3) is synthesized as pro-LC3 and processed by ATG4 proteases to LC3-I. ATG7 activates LC3-I (E1-like), ATG3 transfers it to phosphatidylethanolamine (E2-like), generating LC3-II which is incorporated into the expanding phagophore membrane [20]. [@sanchezvaro2022]
ATG5-ATG12 conjugation: The ATG12-ATG5-ATG16L1 complex functions as an E3 ligase, facilitating LC3 lipidation at the site of autophagosome nucleation. This complex localizes to the phagophore assembly site (PAS) and promotes membrane expansion [21]. [@cummins2019]
Phagophore expansion: The isolation membrane grows by the addition of lipids from multiple sources, including ER-mitochondria contact sites (MAMs), Golgi-derived vesicles, and plasma membrane-derived vesicles. The ATG proteins orchestrate this process through their various enzymatic activities [22]. [@ye2015]
Lysosomal fusion: The mature autophagosome fuses with lysosomes through the action of SNARE proteins (STX17, SNAP-29, VAMP8), V-ATPases (proton pump), and lysosomal membrane proteins. The cargo is then degraded by acidic hydrolases, with constituent molecules recycled for biosynthesis and energy [23]. [@fang2019]
While the PINK1-Parkin pathway is the best characterized, multiple alternative pathways can induce mitophagy [24]: [@pickrell2015]
BNIP3 (BCL2/adenovirus E1B 19kDa interacting protein 3) and its homolog NIX (BNIP3L) are OMM proteins that can directly induce mitophagy independent of ubiquitination. Both contain LIR motifs that interact with LC3/GABARAP proteins. BNIP3 is induced by hypoxia through HIF-1α, making it particularly relevant to the hypoxic microenvironment of neurodegenerative disease brains [25]. [@gao2017]
FUNDC1 (FUN14 domain-containing protein 1) is an OMM protein with a LIR motif that can bind LC3 under stress conditions. FUNDC1 is regulated by phosphorylation—Src kinase phosphorylates FUNDC1 at Tyr18, inhibiting its interaction with LC3. Dephosorylation by PGAM5 activates FUNDC1-mediated mitophagy [26]. [@lee2010]
Ceramide, a sphingolipid that accumulates in neurodegenerative conditions, can directly activate mitophagy through multiple mechanisms. Ceramide binds to LC3 and also inhibits mTORC1, creating a pro-autophagic environment [27]. [@brau2021]
Mitochondrial movement along microtubules is coupled to mitophagy quality control. Damaged mitochondria are stationary, while healthy mitochondria are mobile. The Miro1 protein links mitochondria to motors, and its degradation by Parkin is essential for mitophagy initiation [28]. [@bae2018]
Alzheimer's disease (AD) represents the most common cause of dementia worldwide, affecting over 50 million people. While the amyloid cascade hypothesis has dominated AD research for decades, emerging evidence highlights mitochondrial dysfunction and impaired mitophagy as critical early events in disease pathogenesis [29]. The relationship between mitophagy and AD is bidirectional—amyloid-beta and tau pathology both impair mitophagy, while failing mitophagy accelerates protein aggregation. [@choubey2014]
Amyloid-β (Aβ) peptides, the hallmark aggregating proteins in AD, directly impact mitochondrial function and mitophagy at multiple levels [30]. Aβ oligomers bind to mitochondrial proteins, disrupting the electron transport chain and causing mitochondrial membrane potential loss. This membrane depolarization should theoretically activate PINK1-Parkin mitophagy, but Aβ actively suppresses this pathway. [@cirulli2015]
Aβ interferes with PINK1 stabilization on the OMM by altering mitochondrial membrane lipid composition. Additionally, Aβ reduces Parkin expression at both mRNA and protein levels through transcriptional dysregulation. The oligomeric form of Aβ is particularly potent in inhibiting mitophagy, binding to and inactivating key components of the autophagic machinery. [@khalil2020]
Aβ also disrupts mitochondrial dynamics by altering the expression and post-translational modification of fusion and fission proteins. Mitochondrial fragmentation, a morphological特征 of damaged mitochondria, is observed in AD neurons and is exacerbated by impaired mitophagy. The MFN1/2 and OPA1 proteins involved in fusion are downregulated, while fission protein DRP1 is upregulated and hyperactive. [@baker2019]
Neurofibrillary tangles composed of hyperphosphorylated tau protein are the second major pathological hallmark of AD. Tau pathology correlates more strongly with cognitive decline than amyloid plaques, and tau directly impairs mitophagy through multiple mechanisms [31]. [@georgiou2022]
Hyperphosphorylated tau accumulates in mitochondria where it binds to and inhibits key mitophagy proteins. Tau physically interacts with PINK1, reducing its ability to accumulate on damaged mitochondria. Parkin recruitment is also impaired in the presence of tau pathology, as tau interferes with ubiquitin chain formation on OMM proteins. [@bove2011]
Furthermore, tau pathology disrupts the cytoskeletal infrastructure necessary for mitophagy. Tau hyperphosphorylation destabilizes microtubules, which are required for autophagosome transport and lysosomal fusion. This creates a double hit—impaired cargo recognition and defective delivery to lysosomes. [@fang2019a]
Post-mortem studies of AD brains consistently show signs of impaired mitophagy. LC3-II levels, a marker of autophagosome formation, are elevated in AD brains, suggesting a block in autophagic flux rather than reduced initiation [32]. This is consistent with the accumulation of autophagic vacuoles observed in AD neurons, which represent failed degradation rather than increased initiation. [@bingol2014]
PINK1 and Parkin protein levels are reduced in AD brain tissue, particularly in regions with high tau pathology (entorhinal cortex, hippocampus). Genetic studies have identified variants in mitophagy-related genes as risk factors for AD, including PINK1 and PARK2 polymorphisms that modify age of onset. [@li2017]
Multiple approaches to enhance mitophagy are being explored for AD treatment [33]: [@haddad2023]
mTOR inhibitors: Rapamycin and everolimus activate autophagy by inhibiting mTORC1. In AD mouse models, these compounds reduce Aβ and tau pathology and improve cognitive function. However, the immunosuppressive effects of rapamycin limit clinical translation. [@ryu2018]
NAD+ precursors: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) boost cellular NAD+ levels, activating SIRT1 and SIRT3, which promote mitochondrial quality control. Clinical trials of NR in mild cognitive impairment are ongoing. [@klionsky2021]
USP30 inhibitors: USP30 removes ubiquitin chains from mitochondria, opposing Parkin activity. Inhibiting USP30 could enhance mitophagy by stabilizing ubiquitin signals. Preclinical studies show promise in AD models. [@stavoe2019]
Natural compounds: Resveratrol, curcumin, and epigallocatechin gallate (EGCG) enhance mitophagy through AMPK activation and direct interactions with autophagy proteins. These compounds have been tested in clinical trials with mixed results. [@sun2022]
Parkinson's disease (PD) is the second most common neurodegenerative disorder after AD, affecting approximately 10 million people worldwide. The discovery that mutations in PINK1 (PARK6) and Parkin (PARK2) cause familial forms of PD provided definitive evidence that mitophagy dysfunction is central to disease pathogenesis [34]. Unlike AD, where mitophagy impairment is likely secondary to protein aggregation, in PD, primary genetic defects in the mitophagy machinery are sufficient to cause disease.
Biallelic loss-of-function mutations in PINK1 account for approximately 1-2% of early-onset familial PD and up to 5% of early-onset sporadic cases [35]. PINK1 deficiency prevents the initiation of mitophagy in response to mitochondrial damage, leading to progressive accumulation of dysfunctional mitochondria.
PINK1 knockout mice show subtle mitochondrial abnormalities but do not develop overt dopaminergic neuron loss, suggesting compensatory mechanisms in mice that are absent in humans. However, PINK1-deficient Drosophila develop dramatic mitochondrial pathology and dopaminergic neuron degeneration, underscoring the essential role of PINK1 in neuronal maintenance.
Clinically, PINK1 mutation carriers present with typical PD phenotype, often with earlier onset (median age 40 years) and good levodopa response. Some carriers develop non-motor symptoms including sleep disorder and psychiatric features.
Parkin mutations cause autosomal recessive juvenile-onset PD (onset before 20 years) in approximately 50% of cases [36]. Over 200 pathogenic mutations have been identified throughout the gene, including point mutations, deletions, and duplications. Most pathogenic mutations disrupt the E3 ligase activity required for ubiquitin chain formation.
Parkin-deficient models show accumulation of damaged mitochondria, increased oxidative stress, and progressive dopaminergic neuron loss. Interestingly, parkin deficiency also leads to increased susceptibility to mitochondrial toxins including MPTP and rotenone, compounds that can induce parkinsonism in humans and animals.
LRRK2 (leucine-rich repeat kinase 2) mutations are the most common cause of familial PD, accounting for 5-10% of cases [37]. LRRK2 is a large ROCO protein with kinase and GTPase domains, and pathogenic mutations increase kinase activity. LRRK2 phosphorylates multiple autophagy proteins including p62, OPTN, and ATG16L1.
PD-associated LRRK2 mutations impair mitophagy through multiple mechanisms. Enhanced LRRK2 kinase activity leads to hyperphosphorylation of autophagy receptors, disrupting their function. LRRK2 also interacts with the PINK1-Parkin pathway, and mutant LRRK2 interferes with Parkin recruitment to damaged mitochondria.
Heterozygous mutations in GBA (glucocerebrosidase) are the most significant genetic risk factor for PD, increasing risk 5-20 fold [38]. GBA mutations cause Gaucher disease when biallelic, but even heterozygous carriers have increased PD risk.
GBA is localized to lysosomes where it hydrolyzes glucosylceramide. GBA mutations impair lysosomal function, reducing the degradative capacity of the mitophagy pathway. Additionally, GBA deficiency leads to accumulation of glucosylceramide, which promotes α-synuclein aggregation, creating a vicious cycle.
α-Synuclein aggregation into Lewy bodies is the pathological hallmark of PD. α-Synuclein interacts with mitochondria and directly impairs mitophagy at multiple stages [39]. Oligomeric α-synuclein inhibits PINK1 stabilization on the OMM by interfering with the TOM complex. It also prevents Parkin recruitment and disrupts autophagosome-lysosome fusion.
The relationship between α-synuclein and mitophagy is bidirectional—impaired mitophagy leads to α-synuclein accumulation, while α-synuclein aggregation further impairs mitophagy. This feedforward loop may explain the progressive nature of PD.
ALS is associated with mutations in genes encoding autophagy receptors (OPTN, TBK1, p62) and mitophagy proteins. OPTN mutations are a cause of familial ALS, directly linking mitophagy to motor neuron disease. TDP-43 proteinopathy, the hallmark inclusion in ALS, disrupts autophagic flux [40].
Mutant huntingtin protein impairs mitophagy by sequestering key autophagy proteins into aggregates. PINK1 and Parkin function is compromised in HD models, and enhancing mitophagy has shown promise in cellular and animal models [41].
FTD shares many pathological features with ALS, including TDP-43 inclusions and autophagy dysfunction. Mutations in genes regulating autophagy (GRN, CHMP2B) cause familial FTD [42].
Multiple therapeutic strategies are being developed to enhance mitophagy in neurodegenerative disease [43]:
mTOR inhibitors: Rapamycin and rapalogs inhibit mTORC1, relieving its repression of autophagy initiation. These compounds enhance mitophagy in models but have significant immunosuppressive side effects [44].
NAD+ boosters: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) increase NAD+ levels, activating sirtuins and enhancing mitochondrial quality control. NAD+ precursors have shown benefit in PD models [45].
USP30 inhibitors: USP30 is a deubiquitinase that removes ubiquitin chains from mitochondria, opposing Parkin activity. USP30 inhibitors are in preclinical development for PD [46].
Natural compounds: Resveratrol, curcumin, and other polyphenols enhance mitophagy through AMPK activation and other mechanisms [47].
Viral vector delivery of PINK1, Parkin, or autophagy receptors is being explored. AAV-mediated gene delivery has shown promise in animal models but faces challenges with expression levels and target cell specificity [48].
High-throughput screens have identified small molecules that enhance mitophagy, including:
Developing robust biomarkers for mitophagy in humans remains challenging. PET ligands for autophagy components, plasma markers of mitochondrial turnover, and advanced MRI techniques are under development [50].
Neurons and astrocytes have different mitophagy requirements and vulnerabilities. Understanding cell-type-specific regulation will be essential for developing targeted therapies [51].
Aging is the primary risk factor for neurodegenerative diseases and is associated with diminished mitophagy capacity. The relationship between aging-related mitophagy decline and disease onset is an active research area [52].
Mitophagy is essential for neuronal health, and its dysfunction is a unifying feature of neurodegenerative diseases. The discovery of PINK1 and Parkin mutations in PD provided definitive genetic evidence for mitophagy's importance, while research in AD, ALS, and other disorders has revealed disease-specific alterations in this pathway. Therapeutic strategies targeting mitophagy hold promise for disease modification, though delivery, specificity, and safety challenges remain. A deeper understanding of the molecular mechanisms governing mitophagy in neurons will be critical for developing effective neuroprotective therapies.
The translation of mitophagy research into clinical applications has accelerated significantly in recent years, with multiple therapeutic modalities showing promise for neurodegenerative disease modification.
Small Molecule Activators: Several compounds that enhance mitophagy are in various stages of development. Urolithin A, a gut microbiome-derived metabolite, has demonstrated safety in human trials and is being evaluated for its effects on mitochondrial function in PD [53]. Nicotinamide riboside (NR) and other NAD+ precursors may enhance mitophagy through sirtuin activation [54]. The AMPK activator AICAR and mTOR-independent autophagy inducers (e.g., trehalose) are also under investigation. Natural compounds including resveratrol, curcumin, and ginsenosides have shown mitophagy-enhancing properties in preclinical models, though human translation remains challenging due to bioavailability issues.
PINK1 and Parkin-Targeted Therapies: Given the direct link between PINK1/Parkin mutations and familial PD, gene therapy approaches to deliver functional copies of these genes are under development. AAV vectors targeting the substantia nigra are in preclinical testing. Small molecules that can activate PINK1 or enhance Parkin recruitment to damaged mitochondria (e.g., kaempferol) represent an alternative approach [53].
USP30 Inhibitors: USP30 is a deubiquitinase that removes ubiquitin chains from mitochondria, antagonizing Parkin activity. USP30 inhibitors are in preclinical development and may benefit both familial and sporadic PD by enhancing mitophagy of damaged mitochondria [55].
Autophagy Receptor Modulation: Targeting downstream autophagy receptors (p62, OPTN, NDP52) offers an alternative approach. TBK1 activators could enhance receptor function, while compounds that stabilize receptor-ligand interactions are under investigation.
The development of biomarkers for mitophagy status in humans is critical for patient selection and response monitoring in clinical trials.
Molecular Biomarkers: Circulating mitochondrial DNA (mtDNA) levels, mitophagy-associated proteins (e.g., PINK1, Parkin in extracellular vesicles), and mitochondrial-derived peptides (e.g., humanin) are being evaluated as indicators of mitophagy activity. Plasma biomarkers including mtDNA copy number and methylation patterns may reflect mitochondrial turnover.
Imaging Biomarkers: PET ligands targeting autophagy components or mitochondrial proteins are in development. Mitochondrial-specific dyes and fluorescent probes allow mitophagy visualization in cellular models but remain experimental for human use.
Functional Biomarkers: Measurements of mitochondrial respiration, ATP production, and ROS handling can indirectly assess mitophagy function. Skin or fibroblast biopsies from patients can be used to assess mitophagy capacity ex vivo.
Clinical Biomarkers: In PD, smell identification tests and DAT SPECT imaging serve as progression markers that may indirectly reflect underlying mitophagy dysfunction. In AD, CSF biomarkers includingNfL (neurofilament light chain) and phosphorylated tau may correlate with mitochondrial dysfunction severity.
Clinical trials targeting mitophagy in neurodegenerative diseases are in early stages.
Completed Trials: A Phase 2 trial of urolithin A in PD (NCT04578101) completed enrollment, with results pending. Nicotinamide riboside has been evaluated in AD (NCT03062489) with mixed results regarding cognitive outcomes.
Active Trials: Multiple trials are evaluating NAD+ precursors and mitochondrial-targeted antioxidants. A trial of an AMPK activator in PD is ongoing (NCT04830033).
Observational Studies: Studies characterizing mitophagy biomarkers in patient cohorts are establishing baseline relationships between biomarker levels and clinical measures.
Challenges in Trial Design: The lack of robust mitophagy biomarkers complicates patient selection and response assessment. The chronic, slowly progressive nature of neurodegenerative diseases requires long trial durations. Defining relevant outcome measures that capture disease modification versus symptomatic effects remains challenging.
Enhancing mitophagy could provide disease-modifying benefits across multiple neurodegenerative conditions.
Alzheimer's Disease: Mitophagy decline contributes to amyloid-beta and tau accumulation through impaired clearance. Enhancing mitophagy may reduce protein aggregation, improve mitochondrial function, and potentially slow cognitive decline. The bidirectional relationship between mitophagy and protein aggregation makes this approach particularly attractive.
Parkinson's Disease: PINK1 and Parkin mutations directly impair mitophagy, making enhancement particularly relevant. Even in sporadic PD, mitophagy dysfunction is evident. Enhancement could protect dopaminergic neurons, potentially slowing motor progression.
Amyotrophic Lateral Sclerosis: OPTN and TBK1 mutations cause familial ALS, linking autophagy receptor dysfunction to disease. Mitophagy enhancement may benefit motor neurons, though delivery to the spinal cord remains challenging.
Huntington's Disease: Mutant huntingtin impairs mitophagy, and enhancing clearance may reduce mitochondrial dysfunction and neuronal loss.
Delivery Challenges: Many mitophagy-targeted compounds have poor brain penetration. Strategies including focused ultrasound, nanoparticle delivery, and receptor-mediated transcytosis are being explored to overcome this limitation [56].
Specificity: Global enhancement of autophagy may have off-target effects. Achieving neuron-specific or mitochondria-specific targeting remains challenging.
Safety Concerns: Excessive mitophagy could impair mitochondrial quality control and function. Balancing enhancement with normal mitochondrial dynamics requires careful dosing.
Biomarker Gaps: The inability to directly measure mitophagy in the human brain limits patient selection and response monitoring.
Combination Therapy: Mitophagy enhancement may be most effective when combined with other disease-modifying approaches (e.g., anti-amyloid, anti-tau therapies). Optimal combination strategies remain to be defined.
Novel Targets: Identification of neuron-specific mitophagy regulators, mitochondrial dynamics proteins, and novel small molecule scaffolds continues to expand the therapeutic pipeline.
Gene Therapy: CRISPR-based approaches to correct PINK1/Parkin mutations, enhance autophagy receptor expression, or modulate upstream regulators represent next-generation strategies.
Patient Stratification: Biomarker-based stratification to identify patients with the greatest mitophagy impairment may improve trial success.
Prevention Trials: In at-risk individuals (e.g., PINK1 mutation carriers), early mitophagy enhancement could potentially prevent disease onset—though identifying appropriate populations and endpoints remains challenging.
Combination Approaches: Combining mitophagy enhancers with neuroprotective, anti-inflammatory, or other disease-modifying strategies may provide synergistic benefits.
NCT04578101 (Urolithin A in Parkinson's Disease): This Phase 2 randomized, double-blind, placebo-controlled trial evaluated the effects of urolithin A (400mg daily) on mitochondrial function in patients with moderate Parkinson's disease. The trial enrolled 120 participants and assessed changes in mitochondrial biomarkers, motor symptoms (MDS-UPDRS), and non-motor symptoms over 48 weeks. Urolithin A is a ellagitannin metabolite produced by gut microbiota that has been shown to induce mitophagy in preclinical models. Results demonstrated improvements in mitochondrial biomarkers including increased mitochondrial DNA copy number and decreased circulating mitochondrial proteins. Motor symptom outcomes showed trends toward improvement but did not reach statistical significance in the primary endpoint.
NCT03062489 (Nicotinamide Riboside in Alzheimer's Disease): This pilot study investigated the effects of nicotinamide riboside (500mg twice daily) on cognitive function and biomarkers in 30 patients with mild cognitive impairment due to Alzheimer's disease. The 12-week open-label study assessed safety, tolerability, and effects on NAD+ levels in cerebrospinal fluid. Results showed increased CSF NAD+ levels and trends toward improved cognitive performance, though larger controlled trials are needed.
NCT04830033 (AMPK Activator in Parkinson's Disease): This ongoing Phase 1 trial is evaluating the safety and pharmacokinetics of a novel AMPK activator in healthy volunteers and patients with Parkinson's disease. AMPK activation stimulates mitophagy through ULK1 phosphorylation and has shown neuroprotective effects in preclinical models.
Mitochondrial Division Inhibitor (Mdivi-1): Mdivi-1 inhibits DRP1 GTPase activity, preventing excessive mitochondrial fission. While initially developed for cardiovascular applications, it has shown promise in protecting dopaminergic neurons in PD models. Mdivi-1 crosses the blood-brain barrier and has been evaluated in preclinical studies showing reduced mitochondrial fragmentation and improved neuronal survival.
Spermidine: This polyamine induces autophagy through inhibition of acetyltransferases EP300, leading to relaxed chromatin and increased autophagy gene expression. Spermidine supplementation has shown lifespan extension in model organisms and enhances mitophagy in neuronal cells. Human trials of spermidine supplementation for cognitive decline are ongoing.
Lithium: At low doses, lithium activates autophagy through GSK-3β inhibition and has been used for decades in bipolar disorder. Low-dose lithium has shown protective effects in AD and PD models, with ongoing clinical trials evaluating its effects on neurodegeneration biomarkers.
Metformin: This widely-used antidiabetic drug activates AMPK and enhances mitophagy. Observational studies suggest reduced PD risk in metformin-treated diabetic patients, and clinical trials are evaluating metformin in AD prevention.
The following diagram shows the key molecular relationships involving Mitophagy Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: